Nanobiotix's stock soars after entering licensing, development deal with J&J's Janssen Pharmaceutica
Shares of Nanobiotix SA shot up 52.1% toward a 17-month high in premarket trading Monday, after the France-based biotechnology company announced a global licensing and co-development agreement with Johnson & Johnson's (JNJ) Janssen Pharmaceutica NV for its cancer treatment. Under terms of the agreement, Nanobiotix will receive up to $60 million in cash near-term, including $30 million for licensing and up to $30 to help develop for NBTXR3, which is being evaluated for treatment of head and neck cancer. The company will also be eligible for up to $1.8 billion related to potential development, regulatory and sales milestones. The agreement comes after Nanobiotix's stock rocketed 229.1% on May 5, after the company said it entered into a final contract negotiations with a "major global pharmaceutical company" to develop and commercialize NBTXR3. The stock has rallied 41.1% year to date through Friday, while the iShares Biotechnology exchange-traded fund (IBB) has lost 5.3% and the S&P 500 has climbed 14.6%.
-Tomi Kilgore
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
07-10-23 0615ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Stocks to Buy While They’re Trading at Big Discounts
-
Markets Brief: Tech Stocks Lead Ahead of Nvidia Earnings
-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
JPMorgan Investor Day: CEO Dimon Pushes Against More Stock Buybacks at Current Prices
-
Should You Buy and Hold an Artificial Intelligence Portfolio?
-
3 Cheap and Dependable Dividend-Growth Stocks to Buy
-
The Best Bank Stocks to Buy
-
After Earnings, Is Roblox Stock a Buy, Sell, or Fairly Valued?
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business